-
6 Biotechnology Stocks Moving In Wednesday's Pre-Market Session
Wednesday, February 5, 2020 - 7:42am | 185Read More...Gainers • Moleculin Biotech, Inc. (NASDAQ:MBRX) stock rose 35.2% to $1.19 during Wednesday's pre-market session. • Arbutus Biopharma, Inc. (NASDAQ:ABUS) shares rose 33.1% to $3.74. The most recent rating by JMP Securities, on February 05, is at Market Outperform, with a price target...
-
15 Biotechnology Stocks Moving In Thursday's After-Market Session
Thursday, January 23, 2020 - 11:28pm | 459Read More...Gainers • Alector, Inc. (NASDAQ:ALEC) stock rose 10.8% to $25.79 during Thursday's after-market session. The most recent rating by BTIG, on November 21, is at Buy, with a price target of $28.00. • Therapix Biosciences, Inc. (NASDAQ:TRPX) stock moved upwards by 6.1% to $0.61....
-
146 Biotechnology Stocks Moving In Thursday's Session
Thursday, January 23, 2020 - 12:47pm | 4326Read More...Gainers • Sierra Oncology, Inc. (NASDAQ:SRRA) stock increased by 3638.9% to $13.00 during Thursday's regular session. The most recent rating by Oppenheimer, on December 06, is at Outperform, with a price target of $1.20. • Innovate, Inc. (NASDAQ:INNT) stock increased by 43.1%...
-
98 Biotechnology Stocks Moving In Wednesday's Session
Wednesday, January 22, 2020 - 1:33pm | 2829Read More...Gainers • Neurotrope, Inc. (NASDAQ:NTRP) stock increased by 131.7% to $3.36 during Wednesday's regular session. • Genprex, Inc. (NASDAQ:GNPX) shares moved upwards by 51.3% to $1.74. • Trillium Therapeutics, Inc. (NASDAQ:TRIL) stock moved upwards by 31.4% to $3.64. • Aevi...
-
20 Biotechnology Stocks Moving In Tuesday's After-Market Session
Tuesday, January 21, 2020 - 11:35pm | 532Read More...Gainers • Genprex, Inc. (NASDAQ:GNPX) stock increased by 18.3% to $1.36 during Tuesday's after-market session. • BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares rose 7.8% to $3.16. According to the most recent rating by Bank of America, on November 15, the current rating is at Buy...
-
Transgemonic Up Another 33% Following Yesterday's 295% Run
Friday, January 13, 2017 - 8:38am | 300Read More...Transgenomic Inc (NASDAQ: TBIO), a nano-cap biotechnology engaged in advancing personalized medicine for the detection and treatment of cancer, skyrocketed higher by 295 percent Thursday. Transgenomic's stock gained $0.84 per share Thursday and closed at $1.12 after hitting an intra-day high of $1....
-
Halozyme Achieves Endpoint In Pancreatic Cancer Study, But Not Everyone Is Bullish
Thursday, January 5, 2017 - 9:56am | 505Read More...Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company focused on developing and commercializing novel oncology products that target tumor microenvironment, gained more than 10 percent Thursday morning. Investors and traders were buying Halozyme's stock after the company...
-
4 Big Biotech Losers Heading Into The New Year
Friday, December 30, 2016 - 10:46am | 656Read More...Here is a look at some of the largest declining biotech names during the final week of 2016. Anthera Anthera Pharmaceuticals Inc (NASDAQ: ANTH) focuses on the development of products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune...
-
6 Biotechs Still Awaiting December Catalysts
Tuesday, December 13, 2016 - 1:53pm | 608Read More...The bottom half of December will prove to be a busy one for the biotechnology sector. Below are six biotech companies with catalysts still ahead for the end of the year. Roche Holding Roche Holding Ltd. (ADR) (OTC: RHHBY)'s Genentech unit's OCREVUS's Prescription Drug User Fee Act (PDUFA) date is...
-
Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma
Wednesday, September 21, 2016 - 6:21am | 373Read More...Allergan plc Ordinary Shares (NYSE: AGN) paid a hefty premium of 159 percent to acquire Vitae Pharmaceuticals Inc (NASDAQ: VTAE) last week, but that figure pales in comparison to the premium attached to its acquisition of Tobira Therapeutics Inc (NASDAQ: TBRA). Allergan will pay $533 million in...
-
These Biotechs Are Getting Crushed Following Juno's Cancer Drug Hold
Friday, July 8, 2016 - 10:17am | 347Read More...Juno Therapeutics Inc (NASDAQ: JUNO) announced late Thursday it has received notice from the U.S. Food and Drug Administration that it has placed a clinical hold on its Phase II clinical trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia. The trial,...
-
Slingshot Insights Hosts Informative Call On Moleculin Biotech: Here Are The Details
Wednesday, June 22, 2016 - 8:07am | 381Read More...Slingshot Insights, a crowdfunded expert network that offers investment research tools, conducted an expert call on Moleculin Biotech Inc (NASDAQ: MBRX) AML drug Annamycin last Friday. The goal of the call was to offer investors the opportunity to better understand how the drug differs from...
-
Here's Why Prima BioMed Is Up 15%
Thursday, May 12, 2016 - 7:20am | 285Read More...Shares of Prima BioMed Ltd (ADR) (NASDAQ: PBMD), an Australia-based biotechnology company that is engaged in research, development and commercialization of licensed medical biotechnology, surged higher by more than 20 percent early Thursday morning. Prima BioMed announced it has entered into an...
-
BTIG Comments On Bluebird Bio's Q1 Print, Highlights Future Catalysts
Thursday, May 5, 2016 - 2:07pm | 264Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) were trading lower by 5 percent mid-Thursday afternoon after the company reported its first-quarter results. Bluebird bio said that it lost $1.52 per share on revenue of $1.499 million during the quarter. Wall Street analysts were expecting the company to...
-
StreetSweeper Short Bio-Path: 'Unfortunate' Analyst Support, Little Executive Biotech Experience
Tuesday, April 26, 2016 - 1:16pm | 593Read More...The Street Sweeper's Sonya Colberg published a scathing short thesis on Bio-Path Holdings Inc (NASDAQ: BPTH), a clinical-stage biotechnology company that focuses on developing drugs to fight cancer. Colberg's main criticism of the company is the fact that it "spent six years...
